These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 14565655

  • 1. Phase II trial of irinotecan (CPT-11) in relapsed or refractory non-Hodgkin's lymphomas.
    Ribrag V, Koscielny S, Vantelon JM, Fermé C, Rideller K, Carde P, Bourhis JH, Munck JN.
    Leuk Lymphoma; 2003 Sep; 44(9):1529-33. PubMed ID: 14565655
    [Abstract] [Full Text] [Related]

  • 2. Irinotecan in relapsed or refractory non-Hodgkin's lymphoma.
    Sarris AH, Romaguera J, Hagemeister FB, Rodriguez MA, McLaughlin P, Pro B, Younes A, Mesina O, Cabanillas F, Medeiros LJ, Samuels B.
    Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):53-6. PubMed ID: 11497233
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Combination phase I/II study of irinotecan hydrochloride (CPT-11) and carboplatin in relapsed or refractory non-Hodgkin's lymphoma. CPT-11/Lymphoma Study Group.
    Tobinai K, Hotta T, Saito H, Ohnishi K, Ohno R, Ogura M, Ariyoshi Y, Takeyama K, Kobayashi T, Ohashi Y, Shirakawa S.
    Jpn J Clin Oncol; 1996 Dec; 26(6):455-60. PubMed ID: 9001351
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience.
    Cosetti M, Wexler LH, Calleja E, Trippett T, LaQuaglia M, Huvos AG, Gerald W, Healey JH, Meyers PA, Gorlick R.
    J Pediatr Hematol Oncol; 2002 Feb; 24(2):101-5. PubMed ID: 11990694
    [Abstract] [Full Text] [Related]

  • 8. Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
    Younes A, Preti HA, Hagemeister FB, McLaughlin P, Romaguera JE, Rodriguez MA, Samuels BI, Palmer JL, Cabanillas F.
    Ann Oncol; 2001 Jul; 12(7):923-7. PubMed ID: 11521796
    [Abstract] [Full Text] [Related]

  • 9. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
    Rothenberg ML, Cox JV, DeVore RF, Hainsworth JD, Pazdur R, Rivkin SE, Macdonald JS, Geyer CE, Sandbach J, Wolf DL, Mohrland JS, Elfring GL, Miller LL, Von Hoff DD.
    Cancer; 1999 Feb 15; 85(4):786-95. PubMed ID: 10091755
    [Abstract] [Full Text] [Related]

  • 10. Chemotherapy with irinotecan (CPT-11), a topoisomerase-I inhibitor, for refractory and relapsed non-Hodgkin's lymphoma.
    Takagi T, Saotome T.
    Leuk Lymphoma; 2001 Aug 15; 42(4):577-86. PubMed ID: 11697485
    [Abstract] [Full Text] [Related]

  • 11. A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy.
    Kakolyris S, Souglakos J, Agelaki S, Kourousis CH, Mavroudis D, Sarra E, Malliotakis P, Georgoulias V.
    Lung Cancer; 2000 Dec 15; 30(3):193-8. PubMed ID: 11137204
    [Abstract] [Full Text] [Related]

  • 12. Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
    Tsavaris N, Ziras N, Kosmas C, Giannakakis T, Gouveris P, Vadiaka M, Dimitrakopoulos A, Karadima D, Rokana S, Papalambros E, Papastratis G, Margaris H, Tsipras H, Polyzos A.
    Cancer Chemother Pharmacol; 2003 Dec 15; 52(6):514-9. PubMed ID: 14504920
    [Abstract] [Full Text] [Related]

  • 13. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL, Figgitt DP.
    Drugs; 2003 Dec 15; 63(8):803-43. PubMed ID: 12662126
    [Abstract] [Full Text] [Related]

  • 14. Irinotecan hydrochloride for the treatment of recurrent and refractory non-Hodgkin lymphoma: a single institution experience.
    Sugiyama K, Omachi K, Fujiwara K, Saotome T, Mizunuma N, Takahashi S, Ito Y, Aiba K, Horikoshi N.
    Cancer; 2002 Feb 01; 94(3):594-600. PubMed ID: 11857289
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Phase I study of irinotecan in pediatric patients with malignant solid tumors.
    Mugishima H, Matsunaga T, Yagi K, Asami K, Mimaya J, Suita S, Kishimoto T, Sawada T, Tsuchida Y, Kaneko M.
    J Pediatr Hematol Oncol; 2002 Feb 01; 24(2):94-100. PubMed ID: 11990713
    [Abstract] [Full Text] [Related]

  • 18. Successful salvage therapy of irinotecan for relapsed Hodgkin's lymphoma.
    Urushihata K, Koizumi T, Kaneki T, Yamaguchi S, Fujimoto K, Kubo K.
    Intern Med; 2002 Aug 01; 41(8):648-50. PubMed ID: 12211535
    [Abstract] [Full Text] [Related]

  • 19. Salvage chemotherapy with CPT-11 for recurrent oligodendrogliomas.
    Chamberlain MC.
    J Neurooncol; 2002 Sep 01; 59(2):157-63. PubMed ID: 12241109
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.